Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc., a company advancing medicines to better treat addictions and drug overdose, announced that the U.S. Food and Drug Administration has granted fast track designation for OP...